The North America microcarriers market was valued at USD 442 million in 2025 and is expected to reach USD 1,215 million by 2035, expanding at a CAGR of 9.7% from 2024 to 2035. The growing need for scalable cell-based biomanufacturing, especially in cell therapy and vaccine applications, is driving market expansion across North America.
The economic impact of tariffs on "North America Microcarriers Market".
Market Growth Drivers
Increasing Adoption in Cell Therapy & Regenerative Medicine: The escalating prevalence of chronic diseases and advancements in cell and gene therapy have propelled the adoption of microcarriers for large-scale cell culture. For instance, Thermo Fisher Scientific has expanded its innovative microcarrier solutions like the Gibco microcarrier product line, enhancing efficient cell expansion processes, thereby supporting the rapid growth of regenerative medicine and cell therapy in the region.
Pharmaceutical Industry Demand for Vaccine Production: The COVID-19 pandemic and subsequent focus on pandemic preparedness and vaccine production have increased the demand for microcarriers in bioprocessing applications. Companies such as Corning Incorporated have reported a surge in their life sciences segment, driven by their microcarrier systems supporting vaccine and biologics production in various pharmaceutical manufacturing setups.
Market Trends
Integration of Automated Bioprocessing Technologies: Key market players like Eppendorf and Sartorius have introduced automated microcarrier-based bioprocessing platforms that integrate process control, real-time analytics, and automation to ensure scalable and consistent cell culture. These smart systems are increasingly adopted by biotechnology companies looking to reduce manual errors and improve reproducibility in cell manufacturing workflows.
Shift Towards Xeno-Free and Chemically Defined Microcarriers: There is a rising preference for xeno-free and chemically defined microcarrier systems to ensure compliance with regulatory guidelines for clinical-grade cell production. Companies such as Pall Corporation have developed advanced xeno-free microcarriers enabling safer cell expansion for clinical applications, addressing the need for high safety and reproducibility in stem cell research and therapeutic manufacturing.
Market Opportunity
Expansion of Contract Manufacturing in Cell-Based Therapies: The increasing outsourcing trend among biotech and pharma companies to contract development and manufacturing organizations (CDMOs) creates significant opportunities for microcarrier suppliers, as seen in recent collaborations with Lonza and Thermo Fisher Scientific to scale cGMP manufacturing of cell therapies.
Emergence of 3D Cell Culture for Drug Discovery: Microcarriers are increasingly used in advanced 3D cell culture systems, supporting more physiologically relevant drug screening platforms. This trend is being harnessed by innovators like CytoSolve and Corning to provide new microcarrier products for pharmaceutical R&D.
North America Microcarriers Market Revenue (USD Million), 2020-2035
The chart illustrates the steady and significant growth in the North American microcarriers market from 2020 to 2035. Starting at USD 262 million in 2020, the market shows a consistent upward trajectory, crossing USD 442 million in 2025, and reaching a projected USD 1,215 million by 2035. The industry’s accelerated adoption in advanced bioprocessing, cell therapy, and vaccine production underpins this robust growth. The CAGR of 9.7% reflects expanding opportunities and strong investments in life sciences and pharmaceutical manufacturing throughout North America.
North America Microcarriers Market by Regions Share (%), 2025
The 2025 regional market share pie chart highlights the United States as the dominant contributor, accounting for 71% of the total North American market value. Canada follows with a 19% share, while Mexico holds 7%. Other regions, comprising Puerto Rico and others, collectively contribute 3%. This imbalance underscores the US’s robust cell therapy and bioprocessing markets, driven by heavy R&D investments, significant healthcare infrastructure, and the presence of global market leaders. Canada and Mexico are poised for higher future growth rates as innovation and pharmaceutical investments rise.
Recent Market Developments
In March 2024, Thermo Fisher Scientific launched a new Gibco microcarrier platform designed for large-scale stem cell expansion to support cGMP-compliant cell therapy manufacturing. This platform incorporates xeno-free, ready-to-use microcarriers, enabling safer and highly efficient cell scaling - a move that strengthens the company’s leadership in cell therapy bioprocessing solutions targeting the North American and global markets.
In May 2024, Corning Incorporated announced the commercialization of their next-generation Corning Synthemax II Microcarrier. The product is engineered to enhance cell attachment in chemically defined conditions, catering to pharmaceutical manufacturers focusing on regenerative medicine and cell-based vaccines. This development aims to meet the growing regulatory and performance demands for clinical-grade cell culture and therapy production in the US and Canada.
In April 2024, Sartorius completed the acquisition of a US-based microcarrier supplier, CellSpring, expanding Sartorius’ microcarrier product portfolio and technology base. This acquisition is expected to accelerate the development of advanced microcarrier solutions for biologics and cell therapy manufacturing, strengthening Sartorius’ North American footprint and R&D capabilities.
Press Releases